Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry

Authors Klaus Braun, Manfred Wiessler, Volker Ehemann, Ruediger Pipkorn, Herbert Spring, et al

Published 4 January 2009 Volume 2008:2 Pages 289—301


Review by Single-blind

Peer reviewer comments 2

Klaus Braun1, Manfred Wiessler1, Volker Ehemann2, Ruediger Pipkorn3, Herbert Spring4, Juergen Debus5, Bernd Didinger5, Mario Koch3, Gabriele Muller6, Waldemar Waldeck6

1German Cancer Research Center, Dept of Imaging and Radiooncology, Heidelberg, Germany; 2University of Heidelberg, Institute of Pathology, Heidelberg, Germany; 3German Cancer Research Center, Central Peptide Synthesis Unit, Heidelberg, Germany; 4German Cancer Research Center, Dept of Structural Analysis of Gene Structure and Function, Heidelberg, Germany; 5University of Heidelberg, Dept of Radiation Oncology, Heidelberg, Germany; 6German Cancer Research Center,Division of Biophysics of Macromolecules, Heidelberg, Germany

Abstract: Recurrent glioblastoma multiforme (GBM), insensitive against most therapeutic interventions, has low response and survival rates. Temozolomide (TMZ) was approved for second-line therapy of recurrent anaplastic astrocytoma. However, TMZ therapy in GBM patients reveals properties such as reduced tolerability and inauspicious hemogram. The solution addressed here concerning GBM therapy consolidates and uses the potential of organic and peptide chemistry with molecular medicine. We enhanced the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly efficient chemotherapeutic TMZ. The TMZ connection to transporter molecules (TMZ-BioShuttle) was investigated, resulting in a much higher pharmacological effect in glioma cell lines and also with reduced dose rate. From this result we can conclude that a suitable chemistry could realize the ligation of pharmacologically active, but sensitive and highly unstable pharmaceutical ingredients without functional deprivation. The TMZ-BioShuttle dramatically enhanced the potential of TMZ for the treatment of brain tumors and is an attractive drug for combination chemotherapy.

Keywords: drug delivery, carrier molecules, facilitated transport, glioblastoma multiforme, temozolomide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

High glucose inhibits ClC-2 chloride channels and attenuates cell migration of rat keratinocytes

Pan F, Guo R, Cheng W, Chai L, Wang W, Cao C, Li S

Drug Design, Development and Therapy 2015, 9:4779-4791

Published Date: 28 August 2015

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR

Vascular Health and Risk Management 2014, 10:237-246

Published Date: 25 April 2014

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Four cases of endophthalmitis after 25-gauge pars plana vitrectomy

Mutoh T, Kadoya K, Chikuda M

Clinical Ophthalmology 2012, 6:1393-1397

Published Date: 28 August 2012

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Inoue K, Iwasa M, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:1315-1319

Published Date: 15 August 2012

Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting

Vogt A, Schoelmerich A, Pollner F, Schlitt M, Raaz U, Maegdefessel L, Reindl I, Buerke M, Werdan K, Schlitt A

Vascular Health and Risk Management 2011, 7:693-699

Published Date: 22 November 2011

The diagnostic value of endothelial function as a potential sensor of fatigue in health

Yoshiko Ohno, Teruto Hashiguchi, Ryuichi Maenosono, et al

Vascular Health and Risk Management 2010, 6:135-144

Published Date: 9 March 2010

Sleep restriction increases white blood cells, mainly neutrophil count, in young healthy men: A pilot study

Karim Zouaoui Boudjeltia, Brice Faraut, Patricia Stenuit, Maria José Esposito, Michal Dyzma, et al

Vascular Health and Risk Management 2008, 4:1467-1470

Published Date: 5 December 2008

Lower eyelid lengthening surgery targeting the posterior layer of the lower eyelid retractors via a transcutaneous approach

Hirohiko Kakizaki, Masahiro Zako, Masayoshi Iwaki

Clinical Ophthalmology 2007, 1:141-147

Published Date: 15 September 2007

Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)

Usha Panchapakesan, Siska Sumual, Carol Pollock

International Journal of Nanomedicine 2007, 2:33-38

Published Date: 15 April 2007